Hubei: 33 commonly used drugs began to be purchased in quantities (list attached)

1, 33 commonly used drugs, began to take the purchase of November 13, Hubei Health Insurance Bureau issued "on the implementation of the first batch of drugs in Hubei Province centralized band procurement notice", officially disclosed the first collection of varieties in Hubei.
According to Cypress Blue Combs, hubei Province's first batch of volume procurement catalog included a total of 33 drugs - involving dosso-tea-alkali, fluoxysacin, cycloproxacin, gatisar, left oxyfluorosa, amoxicerin, ticassin and so on.
note that these 33 drugs are injections, and sartar, xilin antibacterial drugs accounted for the vast majority.
In the selection method of the procurement varieties with volume, Hubei also pointed out that in accordance with the principle of large clinical use, high procurement amount and full market competition, the above-than-annual provincial procurement platform drug transaction amount and the actual use amount of medical institutions, according to the general name of the drug statistical amount from high to low in order, the amount of the top drug batch into the scope of the proposed belt procurement.
It is worth noting that, according to the characteristics of regional drug use, the first batch of drugs centralized procurement in Hubei Province entrusted to the Wuhan Municipal Health Insurance Bureau specific operations, after the batch of drug centralized belt procurement, depending on the circumstances entrusted to other qualified municipal and state health insurance bureau specific operations.
centralized volume procurement documents and results issued by the provincial health insurance bureau to the province for implementation.
the provincial health insurance bureau, the city health insurance bureau specific operation, this local collection of practice forms worthy of attention.
Previously, on some irregular issues of municipal collection, the leaders of relevant departments in their speeches also mentioned that in order to standardize local collection, provincial platforms need to coordinate planning, strengthen the leadership of the area of collection and harvesting work, including the collection of local cities, alliance of mining.
At the same time that the state organizes the normalization of drug collection, provincial collection, cross-provincial alliance, city alliance in many places flowering, the country, province and city for the clinical use of large quantities of drugs are carrying out their own volume procurement, the three levels of collection between the linkage, coordination, order is worthy of attention.
2, collection of drugs, multi-category division of the first round of hubei with volume procurement also has a noteworthy place is that, in the simultaneous release of the "Hubei Province drug centralized belt procurement catalog classification method", Hubei will be with the volume of procurement of drugs for a variety of categories of classification - according to the general name classification (chemical and biological products, Chinese medicine and natural medicine), by dosage form classification, by specification classification, according to packaging material classification, a total of 6 other classification methods.
on the issue of classification by dosage form, some industry sources told Cypress Blue, if the improvement of dosage forms can appropriately raise the price of recruitment, then the research and development of pharmaceutical companies is also a driving force.
In addition, Hubei also divided pharmaceutical companies into two bidding groups according to the corresponding conditions: the first group is mainly a national class of new drugs;
group is mainly other GMP-certified drugs and other imported drugs.
, comprehensive evaluation will be conducted on the industry ranking, innovation ability, product output, raw material protection, clinical efficacy, market share, etc.
3, provincial recruitment, distinguish between different bidding groups Before, WeChat public number fengyun drug talk in an article pointed out that Jiangxi, Shandong, Zhejiang, Henan and other provinces have adopted the drug companies into different bidding groups of the recruitment strategy.
There is an analysis pointed out that, because the current provincial collection of selected varieties to over-consistent evaluation of less than 3 products, in this group mode, it is easy to appear the original research group of competitive pharmaceutical enterprises, not more than the consistency evaluation group of competitive pharmaceutical enterprises, and finally appeared, the original research group small price reduction can be selected, but not after the consistency evaluation group between the drug companies to kill fierce, significant price reduction situation, especially the original research group's small price reduction will not affect the impact of the purchase price reduction effect.
May be to reduce the occurrence of this situation, Zhejiang Province's collection documents have innovative provisions - the quotation enterprises are divided into A, B two groups, Group A for the original research drugs or competition preparations, Group B for other generic drugs.
Zhejiang Province regulations, such as A, B in any group of streaming standards, then the group agreed to purchase 50% of the amount of agreed procurement into another group of agreed procurement volume, the remaining 50% as the agreed purchase amount of the remaining amount - some analysts pointed out that this is to give foreign enterprises more pressure to reduce prices.
4, should I be grouped? On this issue, an industry insider, who did not want to be named, said that before the lack of consistent evaluation, the bidding everywhere is basically separate from the original research and domestic drugs, the original research drug companies tender price has been significantly higher than the domestic generic drugs.
With the country for the over-consistent evaluation of three varieties to carry out volume procurement, the over-consistent evaluation of generic drugs and original research drugs as the same quality level, to promote the two types of drugs in the same competition, only to truly achieve the price of the original drug decline, and play the alternative effect of generic drugs.
However, it should not be overlooked that the realization of this result has a pre-condition is the generic drug consistency evaluation, there is a view that before the generic drug consistency evaluation, domestic generic drugs and original drugs can not compete in the same group, because it is not possible to prove that its quality and efficacy and original research drugs are consistent.
Beijing Sheng Shikang to Chinese medicine marketing planning company chairman Shen Yong on the Saibailan said that the original pharmaceutical enterprises as a pharmaceutical first production enterprises for the drug is the most understanding, although after the patent period, but in the production technology and other aspects still have certain advantages.
However, there are different views in the industry on this issue - he pointed out to Seberland that while foreign companies generally want to group, some provinces do not take grouping measures, on the grounds that although consistency evaluation is a quality standard, there is no direct relationship with the need for grouping.
On the issue of provincial collection bidding grouping, Seberlan's special author, Code Wanxuan, told Cypress Blue that the grouping should be viewed dialectically and that the two issues of "should not be grouped" and "how many groups should be divided" should be considered together.
, grouping should be grouped, but not too fine.
in general, many provinces do not agree to adopt the "different bidding group" recruitment strategy, more confirmed that the centralized procurement mechanism of drugs is to recognize the market supply, seize the market demand under the premise of development.
drug collection policy to achieve product bidding is not the only goal, to promote the inheritance and development of excellent products, advanced product innovation and upgrading is also a priority.
Just as the national drug negotiations to import anti-cancer drugs as the main body, in the national economy "double cycle" of the new period, by the General Administration of Market Supervision, NMPA and CDE recognized the value of domestic listed products have been quite a lot, for this group of products, the role of the procurement mechanism with volume is to support reasonable volume, reasonable quotations, for another group to do a price model.
group or not? How fine is it? At present, there is no unified opinion in the industry, but there are authoritative opinions can be used as a reference - at a meeting, the relevant leaders have said that some grouping rules, influenced by interest groups, have a certain tendency, emphasizing that grouping reduces competition between enterprises, protects the vested interests of some enterprises, and also reduces the role of the inquiry mechanism.
original title: 33 commonly used medicines, with volume purchase start (with list)